Asenapine for the Treatment of Psychotic Disorders: A Systematic Review and Meta-analysis

Canadian Journal of Psychiatry

Volumn 62, Issue 2, 2017, Pages 123-137

  Orr, Catherine ^a   Deshpande, Santosh ^a   Sawh, Sonja ^a   Jones, Philip M ^b   Vasudev, Kamini ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

asenapine; asenapine maleate; psychosis; randomized clinical trials; Saphris; schizoaffective disorder; schizophrenia; Sycrest

Indexed keywords

ASENAPINE; OLANZAPINE; TRIACYLGLYCEROL; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

ADVERSE DRUG REACTION; CLINICAL GLOBAL IMPRESSION SCALE; COCHRANE LIBRARY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INSOMNIA; LONG TERM CARE; META ANALYSIS; METABOLIC SYNDROME X; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; PSYCINFO; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SHORT COURSE THERAPY; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; PSYCHOTIC DISORDERS;

EID: 85011628892     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/0706743716661324     Document Type: Review

References (25)

1. Public Health Agency of Canada. Schizophrenia [Internet]. 2012. [cited 2013 Sep 7]. http://www.phac-aspc.gc.ca/publicat/miic-mmac/chap-3-eng.php
2. Crismon L, Argo TR, Buckley PF.,. Chapter 76. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 8th ed [Internet]. 2011 [cited 2013 Sep 7]. Available from: http://www.accesspharmacy.com/content.aspx?aID=7987911
3. Merck. Saphris: drug product monograph [Internet]. In: e-CPS. Ottawa (ON): Canadian Pharmacist Association; 2011. [cited 2013 Sep 7]. Available from: https://www.e-therapeutics.ca/cps.select.preliminaryFilter.action?simplePreliminaryFilter=asenapine+maleate#
4. Lilly. Zyprexa [Internet]. In: e-CPS. Ottawa (ON): Canadian Pharmacist Association; 2013. [cited 2013 Sep 7]. Available from: https://www.e-therapeutics.ca/cps.select.preliminaryFilter.action?simplePreliminaryFilter=olanzapine
5. Health Canada, Drug Product Database. Saphris drug product monograph. Kirkland (QC): Merck Canada Inc; 2011.
6. Rado J, Janicak P,. Pharmacological and clinical profile of recently approved second-generation antipsychotics implications for treatment of schizophrenia in older patients. Drugs Aging. 2013; 29: 783-791.
7. Szegedi A, Verweij P, Van Duijnhoven W, Mackle M, Cazorla P, Fennema H,. Meta analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics. J Clin Psychiatry. 2012; 73 (12): 1533-1540.
8. Mills E, Thorlund K, Loannidis J,. Research methods and reporting: demystifying trial networks and network meta analysis [Internet]. BMJ 2013. [cited 2014 Nov 20]. Available from: http://www.bmj.com/content/346/bmj.f2914
9. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009; 166 (2): 152-163.
10. De Hert M, Yu W, Detraux J, Sweera K, Van Winkel R, Correll C,. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder a systematic review and exploratory meta-analysis. CNS Drugs. 2012; 26 (9): 733-759.
11. Leucht S, Cipriani A, Spineli L, Mavridis D, Crey D,. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382: 951-962.
12. Higgins JPT, Deeks JJ, Altman DG,. Chapter 16: Special topics in statistics. Section 16.5.4: Studies with more than two intervention groups. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions (Version 5.1.0) [Internet]. The Cochrane Collaboration [cited 2014 May 15]. Available from: http://handbook.cochrane.org/
13. Sterne JAC, Egger M, Moher D,. Chapter 10: Addressing reporting biases. Section 10.4.4.1: Comparing fixed and random effects estimates. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions (Version 5.1.0) [Internet]. The Cochrane Collaboration [cited 2015 Jun 6]. Available from: http://handbook.cochrane.org/
14. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions [Internet]. Version 5.1.0 [updated March 2011]. London (UK): The Cochrane Collaboration; 2011. [cited 2014 Mar 20]. Available from: http://handbook.cochrane.org/
15. Higgins JPT, Deeks JJ,. Chapter 10: Addressing reporting biases. Section 10.4.3.1: Recommendations on testing for funnel plot asymmetry. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions (Version 5.1.0) [Internet]. The Cochrane Collaboration [cited 2016 Jun 20]. Available from: http://handbook.cochrane.org/
16. Buchanan R, Panagides J, Zhao J, Phiri P, Hollande W, Ha X,. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012; 321 (1): 36-45.
17. Kane J, Cohen M, Zhao J, Alphs L, Panagides J,. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010; 30 (2): 106-115.
18. Kane J, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J,. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry. 2011; 72 (3): 349-355.
19. Potkin S, Cohen M, Panagides J,. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007; 68 (10): 1492-1500.
20. Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R,. Long-term assessment of asenapine versus olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010; 43: 138-146.
21. Chapel S, Hutmacher M, Haig G, Bockbrader H, Greef R, Preskorn S,. Exposure-response analysis in patients with schizophrenia to assess the effects of asenapine on QTc prolongation. J Clin Psychiatry. 2009; 49: 1297-1308.
22. Laughren T,. Department of Health and Human Services Public Health Service Food and Drug Administration, Center for Drug Evaluation and Research. Recommendation for approval action for asenapine sublingual tablets for the acute treatment of schizophrenia and for the acute treatment of mania or mixed episodes in bipolar 1 disorder 2009 (22-117) [Internet] [cited 2014 Apr 10]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/022117s000-MedR-P1.pdf
23. Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Australian public assessment report for asenapine [Internet]. 2011 [cited 2014 Apr 10]. Available from: http://www.tga.gov.au/auspar/auspar-asenapine
24. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement [Internet]. PLoS Med. 2009; 6 (6): e1000097. [cited 2013 Dec]. Available from: http://www.prisma-statement.org/index.htm
25. Higgins JPT, Deeks JJ, editors. Chapter 7: Selecting studies and collecting data. Section 7.2.4: Implementation of the selection process. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions (Version 5.1.0) [Internet]. The Cochrane Collaboration [cited 2015 Jun 4]. Available from: http://handbook.cochrane.org/